报告题目：Enabling the prevention and control of emerging pathogens by pathogen discovery, vaccine and therapeutic development
时间：2023年12月26日
地点：东校区会议中心学术报告厅
报告摘要：
Recent years, we have faced a serious of outbreaks of emerging and re-emerging infectious diseases including flu, MERS, Ebola, Zika, COVID-19 and mpox. Pathogen discovery is the first step to control the diseases. The rapid obtaining the SARS-CoV-2 genome and isolation of virus in China in the early 2020 provided a basis for the vaccine and therapeutic development over the world. We revealed how SARS-CoV-2 use the receptor human ACE2 for its entry and its different immunogenicity with SARS-CoV, albeit they bind to the same receptor, suggesting the limited benefit of the countermeasures targeting SARS-CoV against SARS-CoV-2 infection. Furthermore, we assessed the receptor binding spectra of SARS-CoV-2 and its variants and elucidated the underlying structural mechanism. Consistently, so far, 38 species have been reported to be naturally infected by SARS-CoV-2. Next, I will introduce our work using structure-guided strategy to design beta-coronavirus (CoV) vaccines against COVID-19, MERS, and SARS, using RBD-dimer as the immunogen. The resulting COVID-19 protein subunit vaccine ZF2001 has completed phase 1, 2, and 3 clinical trials with an efficacy of 81.4%, and was commercially approved. For rapid updating of immunogens against emerging variants, we further developed a chimeric RBD-dimer vaccine approach eliciting broad serum neutralization and protection in animal models and human. The RBD-dimer design has been successfully used as other forms of vaccines,including. DNA,ChAdV-vectored,mRNA etc. Tandem-repeat trimeric RBD vaccine has also been developed. Additionally, to combat the emerging and re-emerging viral pathogens, we set up a platform a few years ago, with the ability to isolate the therapeutic antibodies from the convalescent PBMCs in 1-2 weeks. Using this platform, we have successfully obtained neutralizing antibodies with high potency against Zika virus and Rift valley fever virus. With the previous experience and accumulated knowledge, we were able to rapidly develop antibodies against SARS-CoV-2 during the COVID-19 pandemic. Through collaborations with Junshi and Eli Lilly, we have successfully advanced the translational application of these antibodies. Currently, the global sales of these antibodies have reached one million doses. Based on the mechanism of fusion between viral envelop and cellular membrane, we developed a peptide inhibitor targeting the HR1 of the SARS-CoV S protein and through collaborating with Hybio, we have finished the phase II clinical study in China, showing that its safety and preliminary effectiveness. Notably, HY3000 has also been approved to conduct clinical investigation by U.S. Food and Drug Administration (FDA) on Jan 28, 2023.
主讲人简介：
高福：
中国科学院院士、美国科学院外籍院士、英国皇家学会外籍院士。中华医学会副会长、中国生物工程学会理事长、传染病防治国家科技重大专项技术总师。曾任中国科学院大学存济医学院院长、国家自然科学基金委员会副主任、中国疾控中心主任。
主要从事病原微生物跨宿主传播、感染机制与宿主细胞免疫、抗病毒手段等研究以及公共卫生政策与全球健康策略研究，为新发突发传染病防控提供重要支撑。